A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer

[1] Alao JP(2004)Histone deacetylase inhibitor trichostatin A represses estrogen receptor alpha-dependent transcription and promotes proteasomal degradation of cyclin D1 in human breast carcinoma cell lines Clin Cancer Res 10 8094-8104

[2] Lam EW(2008)Selective inhibition of histone deacetylase 2 silences progesterone receptor mediated signaling Cancer Res 68 1513-1519

[3] Ali S(2001)Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma Cancer 92 2247-2258

[4] Buluwela L(1998)Optimal flexible designs in phase II clinical trials Stat Med 17 2301-2312

[5] Bordogna W(2008)Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT J Clin Oncol 26 1664-1670

[6] Lockey P(2007)Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL) Blood 109 31-39

[7] Varshochi R(2005)Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials Lancet 365 1687-1717

[8] Stavropoulou AV(2009)Lower-dose vs high-dose oral estradiol therapy of hormone receptor-positive, aromatase inhibitor-resistant advanced breast cancer: a phase 2 randomized study JAMA 302 774-780

[9] Coombes RC(2007)Hydroxamic acid analogue histone deacetylase inhibitors attenuate estrogen receptor-alpha levels and transcriptional activity: a result of hyperacetylation and inhibition of chaperone function of heat shock protein 90 Clin Cancer Res 13 4882-4890

[10] Vigushin DM(2009)Phase II trial of vorinostat in recurrent glioblastoma multiforme: a north central cancer treatment group study J Clin Oncol 27 2052-2058

[1] Alao JP(2004)Histone deacetylase inhibitor trichostatin A represses estrogen receptor alpha-dependent transcription and promotes proteasomal degradation of cyclin D1 in human breast carcinoma cell lines Clin Cancer Res 10 8094-8104

[2] Lam EW(2008)Selective inhibition of histone deacetylase 2 silences progesterone receptor mediated signaling Cancer Res 68 1513-1519

[3] Ali S(2001)Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma Cancer 92 2247-2258

[4] Buluwela L(1998)Optimal flexible designs in phase II clinical trials Stat Med 17 2301-2312

[5] Bordogna W(2008)Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT J Clin Oncol 26 1664-1670

[6] Lockey P(2007)Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL) Blood 109 31-39

[7] Varshochi R(2005)Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials Lancet 365 1687-1717

[8] Stavropoulou AV(2009)Lower-dose vs high-dose oral estradiol therapy of hormone receptor-positive, aromatase inhibitor-resistant advanced breast cancer: a phase 2 randomized study JAMA 302 774-780

[9] Coombes RC(2007)Hydroxamic acid analogue histone deacetylase inhibitors attenuate estrogen receptor-alpha levels and transcriptional activity: a result of hyperacetylation and inhibition of chaperone function of heat shock protein 90 Clin Cancer Res 13 4882-4890

[10] Vigushin DM(2009)Phase II trial of vorinostat in recurrent glioblastoma multiforme: a north central cancer treatment group study J Clin Oncol 27 2052-2058